|Application ||WB, IHC-P, FC, E|
|Calculated MW||29626 Da|
|Antigen Region||239-267 aa|
|Other Names||CD82 antigen, C33 antigen, IA4, Inducible membrane protein R2, Metastasis suppressor Kangai-1, Suppressor of tumorigenicity 6 protein, Tetraspanin-27, Tspan-27, CD82, CD82, KAI1, SAR2, ST6, TSPAN27|
|Target/Specificity||This CD82 (ST6) antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 239-267 amino acids from the C-terminal region of human CD82 (ST6).|
|Format||Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.|
|Storage||Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||CD82 (ST6) Antibody (C-term) is for research use only and not for use in diagnostic or therapeutic procedures.|
|Synonyms||KAI1, SAR2, ST6, TSPAN27|
|Function||Associates with CD4 or CD8 and delivers costimulatory signals for the TCR/CD3 pathway.|
|Cellular Location||Membrane; Multi-pass membrane protein.|
|Tissue Location||Lymphoid specific.|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
The ST6 metastasis suppressor gene product is a membrane glycoprotein that is a member of the transmembrane 4 superfamily. Expression has been shown to be downregulated in tumor progression of human cancers and can be activated by p53 through a consensus binding sequence in the promoter. Its expression and that of p53 are strongly correlated, and the loss of expression of these two proteins is associated with poor survival for prostate cancer patients.
Zhang, X.A., et al., J. Biol. Chem. 278(29):27319-27328 (2003).
Zhang, X.A., et al., Cancer Res. 63(10):2665-2674 (2003).
Yang, J., et al., Ai Zheng 22(5):533-536 (2003).
Sauer, G., et al., Oncol. Rep. 10(2):405-410 (2003).
Ito, Y., et al., Pathol Res Pract 199(2):79-83 (2003).
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at email@example.com.